-
100% of patients achieve complete remission of oncolytic virus/PD-1 antibody combination Phase 2 clinical results are positive
Time of Update: 2021-12-02
A few days ago, CG Oncology announced the preliminary results of phase 2 clinical trials of its oncolytic virus therapy CG0070, in combination with the heavy anti-PD-1 antibody Keytruda, in the treatment of non-muscular invasive bladder cancer.
-
How did the United States achieve a 27% reduction in the mortality rate of the 50-year history of anti-cancer?
Time of Update: 2021-12-02
Specifically, these 15 cancers are lung cancer, breast cancer, prostate cancer, colorectal cancer, pancreatic cancer, ovarian cancer, gastric cancer, leukemia, cervical cancer, non-Hodgkin’s lymphoma, bladder cancer, oral and pharynx cancer, Brain and central nervous system cancer, kidney cancer, and esophageal cancer .
-
Keytruda receives FDA approval for the first time to treat early-stage kidney cancer to reduce the risk of recurrence by 32%
Time of Update: 2021-12-02
▲The results of Keytruda in the pivotal Phase 3 clinical trial (Image source: Merck official website)"The adjuvant treatment options for early renal cell carcinoma are limited, and Keytruda's approval provides a new treatment option for patients with a higher risk of recurrence .
-
Functional cure for hepatitis B RNAi and neutralizing antibody therapy go further
Time of Update: 2021-12-02
▲VIR-3434 significantly reduces HBsAg levels (picture source: Vir company official website)Reference materials:[1] Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection at AASLD The Liver Meeting.
-
This food contains almost completely digestible protein
Time of Update: 2021-12-02
A protein with a complete range of essential amino acids and a ratio that meets the needs of the human body is called complete protein, which is what we often call high-quality protein.
-
What is the recommended schedule for eating on time?
Time of Update: 2021-12-02
So, what time is it for nutrition experts to eat on time?The time it takes for the human body to digest and absorb food determines the need for three meals a day and the interval between the three meals .
-
The cure rate is 90%!
Time of Update: 2021-12-02
Merck (Merck) and Pediatric Praziquantel Consortium (Pediatric Praziquantel Consortium, PPC) recently announced that a key phase 3 clinical trial for evaluating single-dose arpraziquantel for the treatment of preschool children (3 months to 6 years old) with schistosomiasis has reached the clinical level The primary end point of cure .
-
Target the "Don't Eat Me" signal!
Time of Update: 2021-12-01
ArticleMedicine GuanlanToday (November 22), the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that the IBI397 declared by Cinda Biologics has obtained an implied license for a clinical trial and intends to develop the treatment of advanced malignant tumors .
-
The metabolic regulation mechanism of non-alcoholic fatty liver malignant transformation has been discovered
Time of Update: 2021-12-01
This study suggests that the activation of the fatty acid metabolism signal axis is an important factor in the formation and maintenance of liver cancer initiating cells, and targeting this signal axis may provide a potential direction for the prevention of non-alcoholic fatty liver NASH-related hepatocellular carcinoma .
-
Zhijiang Bio: The company's new crown detection kit can effectively detect Omicron virus
Time of Update: 2021-12-01
). The results confirm that: Jiang Biological has launched a new coronavirus 2019-nCoV nucleic acid detection kit (fluorescent PCR method), and there will be no off-target and missed detection .
-
Using Raman spectroscopy to detect D3 embryo culture fluid can predict embryo cyst formation rate
Time of Update: 2021-12-01
A latest study from the CITIC Xiangya Hospital team shows that using Raman spectroscopy and deep learning classification models can detect D3 embryo culture and predict the development potential of D3 embryos from cleavage stage to blastocyst stage, with an overall accuracy rate of 73.
-
Bifunctional antibodies for the treatment of autoimmune diseases show a new mode of suppressing immune response
Time of Update: 2021-12-01
Obexelimab is a new type of bifunctional antibody that simultaneously targets FcγRIIb that inhibits B cell activity and CD19 antigen expressed by B cells for the treatment of autoimmune diseases .
-
The image of the "super variant" Omicron spike protein of the swiping world is announced!
Time of Update: 2021-12-01
The spike protein is "the key used by the virus to open the door to human cells", and variants of the new coronavirus with many mutations may bypass the body's immune system .
-
Nobel Prize winner company type 1 diabetes therapy is about to enter clinical diabetes therapy what else
Time of Update: 2021-12-01
to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (Source: CRISPR Therapeutics)
-
Against breast cancer!
Time of Update: 2021-12-01
ArticleMedicine GuanlanThe China Drug Clinical Trial Registration and Information Disclosure Platform shows that Yibaikang Pharmaceutical, a subsidiary of Eteng Jingang, has launched a phase 2 clinical study in China to evaluate recombinant human lymphocyte activation gene-3 (hLAG-3) fusion protein The safety and efficacy of (EOC202) injection combined with albumin paclitaxel in advanced breast cancer patients with hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative endocrine therapy .
-
Preliminary research completed, China has two more anti-coronavirus drugs entering the clinic
Time of Update: 2021-12-01
A few days ago, a reporter from Science and Technology Daily learned from the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences that the two anti-neoplastic drugs developed by the Institute have now completed preclinical studies and entered the clinical trial stage .
-
Macaque model reveals why elderly people with new coronary pneumonia are more sick
Time of Update: 2021-12-01
On November 22, a reporter from Science and Technology Daily learned from the Kunming Institute of Zoology, Chinese Academy of Sciences, that a study by the institute has discovered the immunopathological mechanism of delayed inflammatory response in an elderly rhesus monkey model with new coronary pneumonia, which may provide treatment for patients with new coronary pneumonia New ideas .
-
Enlightenment of Niu Baby Biotin to Drug Design
Time of Update: 2021-12-01
Drug design is like a matchmaking agency, where a ligand that can form a stable complex is found for the target protein .
-
E-cigarette smoking may cause osteoporosis
Time of Update: 2021-12-01
Science and Technology Daily, Beijing, November 24 (intern reporter Zhang Jiaxin) Recently, a new study of more than 5,500 adult e-cigarette users found that e-cigarette use is associated with a high prevalence of fragility fractures.
-
Multiple domestic new crown drugs enter clinical trials
Time of Update: 2021-12-01
From the hundreds of antibodies isolated from the blood of convalescent patients, 2 strains of antibodies with high activity and strong complementarity were screened-the new coronavirus antibody combination drug BRII developed by Tsinghua University, Shenzhen Third People's Hospital and Tengsheng Biopharmaceutical team -196/BRII-198, has recently completed the foreign phase III clinical trials, and has been urgently called by the relevant departments to provide clinical treatment for more than 800 cases of infection in China .
